Mr. Marc Wayne reports

BEDROCAN CANNABIS CORP. REACHES $1 MILLION IN IMPORTED PRODUCT REVENUES

In Bedrocan Cannabis Corp.'s first nine months of operations, the company reached an aggregate of $1-million in revenues, with more than 1,400 registered medicinal cannabis patients. The revenue and patient figures were achieved from first product shipment in late February, 2014, through completion of the company's nine-month period ended Oct. 31, 2014, the interim financial statements in respect of which are expected to be released on SEDAR in December, 2014.

"We are delighted to have reached the $1-million milestone for revenues from product imported from our partner Bedrocan BV in the Netherlands, and it demonstrates that our phase I business strategy, as presented, remains on track," said Marc Wayne, president and chief executive officer. "Patients are responding positively, customer retention is excellent, our customer care and fulfilment process is operating smoothly, and product quality control has been flawless."

Phase II of Bedrocan's business strategy has been initiated, as planned, with construction nearing completion on the company's new 52,000-square-foot production facility in the Greater Toronto Area. The new site is scheduled to be functionally complete in December, 2014, at which time the company will prepare for the required inspection by Health Canada. Upon receipt of a licence to produce from Health Canada, anticipated in early 2015, Bedrocan intends to immediately begin domestic production of up to 4,000 kilograms of medicinal cannabis annually.

"The shift to domestic production in phase II of our business plan will give us much greater capacity to meet increasing customer demand and will build on the product quality and patient trust we have established throughout 2014," said Mr. Wayne. "The medicinal cannabis cultivated at our domestic site will be identical to the product we are now importing -- in terms of plant genetics, production techniques, quality control and product standardization."